Delivery Order SPE2DB25D3404-SPE2DB25FUQAD
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,346.24 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pharmaceutical product on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is performed at the contractor's Conshohocken, Pennsylvania facility. The award is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency awarded a $17,574.35 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen vials under a firm fixed price contract type. This competitive award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery location is specified as Conshohocken, Pennsylvania, the company's corporate...
- The Defense Logistics Agency awarded a $6,119.69 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of SKYRIZI 600 mg/10 mL vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 2, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical supply requirements. This award is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of SKYRIZI 150 mg/mL pen medication, valued at $17,239.18. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The delivery is scheduled for completion by August 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of SKYRIZI 150 mg/ml in pen/ml formulation, with a ceiling value of $24,342.14. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $12,962.95 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of SKYRIZI 150 mg/ml pen injections. This is a firm fixed-price contract with an ultimate completion date of July 28, 2025, and was competitively awarded with no set-aside designation. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive $999,999,999.00...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of SKYRIZI 150 MG/ML PenML, a pharmaceutical product, with a ceiling value of $26,166.64. This competitively awarded, firm fixed-price delivery order is set to conclude on August 19, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,119.69 for SKYRIZI 600 mg/10 mL vials on July 14, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price delivery order is not set-aside and represents a competitive award. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office operations. This delivery order is issued...
- The Defense Logistics Agency awarded a $20,990.24 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of SKYRIZI 150 mg/ml pen/ml, a pharmaceutical product to be delivered to the company's facility in Conshohocken, Pennsylvania. This firm fixed-price delivery order represents a non-competitive set-aside contract and is scheduled for completion by September 5, 2025. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) vehicle with...
- The Defense Logistics Agency awarded a $43,004.55 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of SKYRIZI 150 mg/ml pen vials. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 12, 2025, and performance at the contractor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUQADDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of SKYRIZI 600 mg/10 ml vials, valued at $12,239.38 with a firm fixed price structure. The delivery order is set to be completed by September 16, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This award represents a non-competitive, non-set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, a $999.99 billion prime vehicle designated SPE2DX and running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical supplier to the Defense Health Agency and military healthcare systems. The company's extensive federal contract portfolio demonstrates capability across a broad range of pharmaceutical products and medical supplies. This particular delivery order for SKYRIZI, a specialty pharmaceutical used in treating immunological conditions, exemplifies the company's role in supporting military and federal healthcare procurement needs through the DLA's comprehensive global pharmaceutical support vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.2k | 8/25/25 |